Guyasuta Investment Advisors Inc. Has $1.30 Million Stake in Novartis AG $NVS

Guyasuta Investment Advisors Inc. increased its stake in Novartis AG (NYSE:NVS) by 3.0% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 10,767 shares of the company’s stock after purchasing an additional 313 shares during the quarter. Guyasuta Investment Advisors Inc.’s holdings in Novartis were worth $1,303,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. WPG Advisers LLC acquired a new position in shares of Novartis during the first quarter worth approximately $25,000. Tsfg LLC grew its position in Novartis by 366.0% in the first quarter. Tsfg LLC now owns 233 shares of the company’s stock valued at $26,000 after acquiring an additional 183 shares during the period. MCF Advisors LLC boosted its stake in Novartis by 66.0% in the second quarter. MCF Advisors LLC now owns 264 shares of the company’s stock worth $32,000 after purchasing an additional 105 shares in the last quarter. Alpine Bank Wealth Management acquired a new position in Novartis in the first quarter worth $33,000. Finally, Investment Management Corp VA ADV lifted its stake in shares of Novartis by 172.2% during the first quarter. Investment Management Corp VA ADV now owns 313 shares of the company’s stock valued at $35,000 after acquiring an additional 198 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Wall Street Zen cut Novartis from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Morgan Stanley raised Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target for the company in a report on Friday, August 8th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $118.00 price objective (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $120.33.

Novartis Stock Up 1.2%

NVS stock opened at $123.75 on Friday. The stock’s 50 day simple moving average is $122.31 and its 200 day simple moving average is $116.57. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $130.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The company has a market cap of $261.41 billion, a P/E ratio of 18.01, a price-to-earnings-growth ratio of 1.73 and a beta of 0.63.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, July 17th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $14.05 billion during the quarter, compared to analyst estimates of $13.94 billion. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.97 EPS. On average, research analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.